Clinical trials: Renal Excretion
Liver Transplantation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C…
- Trial name
- REFLECT (NCT02115113)
- Testing
- Everolimus, Tacrolimus
- Where
- 14 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Polycystic Kidney, Autosomal Dominant
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
The aim of the study is to test the following hypotheses: 1. that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease. 2.
- Trial name
- NCT00410007
- Testing
- High Sodium Diet, Low Sodium Diet, Hypertonic saline infusion
- Where
- Denmark
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Carolina Cannillo
Hyperoxaluria, Nephrolithiasis
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
The purpose of this study is to evaluate the effect of ALLN-177 to reduce urinary oxalate excretion in patients with recurring kidney stones and enteric or idiopathic hyperoxaluria.
- Trial name
- NCT02289755
- Testing
- ALLN-177
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Allena Pharmaceuticals
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Osteosarcoma, Leukemia
Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze
The purpose of this study is to investigate whether the administration of Voraxaze reduces exposure to leucovorin and its active metabolite to below the level achieved in patients who have not received Voraxaze.
- Conditions
- Osteosarcoma, Leukemia, Lymphoma
- Trial name
- LVPK (NCT00634504)
- Testing
- glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
- Where
- 25 sites in United States
- Volunteers
- 20 people
- Sponsor
- BTG International Inc.
Urinary Tract Infection, Pyelonephritis
Pharmacokinetics of Ciprofloxacin in Pediatric Patients
Measuring serum and urine concentrations of ciprofloxacin after IV and oral administration in children aged 3 months - 17 years who are treated for urinary tract infections.
- Trial name
- NCT02598362
- Testing
- ciprofloxacin
- Where
- 2 sites in Belgium
- Volunteers
- 22 people
- Sponsor
- University Hospital, Ghent
Chronic Kidney Diseases, Acute Myocardial Infarction
Troponin Excretion in Urine in Patients With and Without Chronic Kidney Disease
In this study, in order to better understand the mechanism of troponin clearance and the reason for elevated troponin levels in patients with CKD, we aim to evaluate quantitatively the excretion of troponin in the urine in…
- Trial name
- NCT04211610
- Testing
- Blood and urine sampling
- Where
- Israel
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Soroka University Medical Center
Reflux, Renal Excretion
Renal Impairment Study
The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.
- Trial name
- NCT00863161
- Testing
- AZD3355
- Where
- 3 sites in Sweden
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetic Nephropathy
Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy
Hypothesis: The angiotensin receptor blocker telmisartan is effective at reduction of albumin excretion rate(AER) in patients with type1 diabetes and micro or macroalbuminuria.
- Trial name
- START1DM (NCT00738660)
- Testing
- Telmisartan, Ramipril
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Inflammation
Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids
To compare the safety and efficacy of cyclosporine (CsA) + mycophenolate mofetil (MMF) + corticosteroids © to CsA + Rapamune + Cs with CsA elimination in the Rapamune arm with the introduction of MMF in de novo renal allograft…
- Trial name
- NCT01601821
- Testing
- CsA+Rapamune+CS, CsA+MMF+CS
- Where
- 4 sites in Iran
- Volunteers
- 245 people
- Sponsor
- Pfizer
Hyperoxaluria (Disorder)
Oxalate Excretion Profile in Patients With a Heterozygous Mutation of the AGXT (Alanine-glyoxylate Aminotransferase) Gene
Primary hyperoxaluria type I (PH1) is a rare genetic disorder responsible for severe lithiasis leading to progressive deterioration of renal function and end-stage renal failure.
- Trial name
- HETEROX (NCT06283082)
- Testing
- Lithiasis assessment
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospices Civils de Lyon
Renal Calculi
Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus
The investigators objective is to study if some drugs can improve the success rate of extracorporeal shockwave lithotripsy for renal stones.
- Trial name
- NCT01215708
- Testing
- Tamsulosin
- Where
- Brazil
- Volunteers
- 136 people
- Sponsor
- University of Sao Paulo General Hospital
Chronic Kidney Disease stage3
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the newest class of orally drugs for the treatment of type 2 diabetes. These drugs decrease plasma glucose levels by inhibiting its reabsorption in the proximal tubules of the…
- Trial name
- NCT04961931
- Testing
- Empagliflozin 10 MG
- Where
- Poland
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Estimated Creatinine Clearance
Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese
It's important to dose according to renal function in who has impaired kidney function. There are two common methods estimating renal function: one is creatinine clearance estimated by Cockcroft-Gault (CG) equation; another is…
- Trial name
- NCT02040181
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Chronic Kidney Diseases, Electrolyte Imbalance
24-hour Urinary Electrolyte Excretion in Chronic Kidney Disease
Association between excretion pattern and development trajectory of urinary electrolytes (urine sodium, urine potassium, urine chlorine, urine magnesium, urine calcium, urine phosphorus, urine creatinine, urea, uric acid, urine…
- Trial name
- NCT05550467
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Kidney Diseases
A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids
The purpose of this study is to compare the risks and benefits of steroid elimination versus steroid therapy in renal transplant patients particularly looking at the effects on bone mass, lipids, hypertension, and new onset…
- Trial name
- NCT00273559
- Testing
- prednisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Florida Hospital Transplant Center
Diabetes Mellitus, Type 2
ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)
This is a prospective 24-week, randomized, parallel-group, multi-center, active-controlled (pioglitazone 45 mg) open-label study designed to assess the effects of tesaglitazar 2 mg per day on components of renal excretion of…
- Trial name
- NCT00229684
- Testing
- Tesaglitazar, pioglitazone
- Where
- 21 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Acute Kidney Injury, Bacterial Infection
Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis
Acute kidney injury (AKI) requiring renal replacement therapy is common in critically ill patients. The major causes of AKI are severe sepsis and septic shock requiring effective antibiotic treatment.
- Trial name
- DIADSORBMAB (NCT02533609)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Chronic Kidney Diseases, Liver Cirrhosis
The Role of the Kidneys and Liver in the Elimination of Glucagon
The study aims to evaluate the kinetics and effect of glucagon in patients with chronic kidney disease and liver cirrhosis and matched healthy subjects, respectively.
- Conditions
- Chronic Kidney Diseases, Liver Cirrhosis, Hyperglucagonemia
- Trial name
- MCR_EndCir (NCT05056584)
- Testing
- Glucagon infusion, Primed tracer infusion
- Where
- Denmark
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Prevention of Thromboembolic Events
Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")
BAY2433334 is under clinical development for prevention of complications in diseases such as heart attack, irregular heart beat or stroke which can arise by formation of blood clots elsewhere in the body and travels through the…
- Trial name
- NCT04510987
- Testing
- BAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5, BAY2433334 on dialysis treatment day
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Bayer